Merck KGaA snaps up BeiGene's 'Made in China' BRAF inhibitor
This article was originally published in Scrip
Executive Summary
In the past, Chinese companies used to act mainly as simple partners to develop and commercialize foreign firms' new drugs in China. But as more companies in this country begin to value innovation over manufacturing, it is now no longer rare for multinationals to seek out and acquire rights to a novel "Made in China" drug for global development.